Taiwan Interstitial Lung Disease Multi-center Investigation and Registry

Sponsor
Taichung Veterans General Hospital
Study ID
NCT06476470
Status
Recruiting
Apply to this trial

Conditions

  • Comorbidities and Coexisting Conditions
  • Function Impaired Respiratory
  • Interstitial Lung Disease
  • Pulmonary Arterial Hypertension
  • Treatment Adherence

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol. Key components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests. The main questions the registry aims to answer are: 1. Differences in all-cause mortality among ILD patients of different etiologies. 2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies. 3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies. 4. Predictive ability of HRCT imaging features for mortality risk in ILD patients. 5. Impact of comorbidities on the mortality risk of ILD patients. 6. Predictive ability of biomarkers for disease progression and mortality.

Key Dates

First listed
Jun 26, 2024
Start date
Mar 10, 2024
Status verified
Jun 2024
Primary completion
Dec 31, 2033
Completion
Dec 31, 2035

Study Design

Enrollment
10,000 participants (estimated)

Primary Outcome Measure

All-cause mortality [ Time Frame: 10 years ]

Central Contacts

Related Studies